Arca
Skip to content
Tools
Tools

Cataract

Drug research and approvals for cataract: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 20, 2026, 142 studies of cataract are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 142
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting now

Newest posted first, of 142 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 6

Phase 3 12 of 22

Phase 2 5

Phase 1 or earlier 3

How its trials ended

1,571 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 232 whose ending is known, 47% met their primary endpoint, 3% missed it and 49% stopped early.

  • Completed, result not reported87155%
  • Status unknown27317%
  • Ongoing19512%
  • Met its primary endpoint1107%
  • Stopped: other or unclear684%
  • Stopped: enrollment or feasibility221%
  • Stopped: sponsor or business decision151%
  • Missed its primary endpoint81%
  • Stopped: lack of efficacy5<1%
  • Stopped: funding3<1%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Oct 16, 2018A randomized controlled trial comparing safety and efficacy of dexamethasone 0.1% and loteprednol etabonate 0.5% after cataract surgeryLotemax (loteprednol) / Maxidex (dexamethasone)Bausch & LombPending
Jan 4, 2018Economic impact of dropless therapy versus usual care for cataract surgery: a real-world studyTriamcinolone acetonide-moxifloxacinImprimis PharmaceuticalsOngoing
Dec 21, 2017A randomized, single-blind, cross-over study of loteprednol etabonate in adults undergoing bilateral cataract surgeryLoteprednolSandozClosed
Jun 28, 2016Comparative effectiveness and safety of 2 dosing regimens of loteprednol gel 0.5% and bromfenac 0.07% solution to control inflammation and pain after cataract…Besifloxacin/ Loteprednol/ BromfenacDr Sohel SomaniPending
Mar 22, 2016The effect of brimonidine on the development of subconjunctival hemorrhage following femtosecond laser assisted cataract surgeryBrimonidineDr. Eric S. TamPending

Medicines authorised in the EU

Newest first
May 18, 2011YelloxBromfenacBausch + Lomb Ireland LimitedEMA ↗
Dec 11, 2007NevanacNepafenacNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.